A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma
Condition(s):NK/T-Cell LymphomaLast Updated:July 29, 2020Unknown status
Hide Studies Not Open or Pending
Condition(s):NK/T-Cell LymphomaLast Updated:July 29, 2020Unknown status
Condition(s):Cutaneous T Cell LymphomaLast Updated:February 20, 2024Active, not recruiting
Condition(s):NK/T Cell LymphomaLast Updated:November 5, 2020Withdrawn
Condition(s):T-Cell LymphomaLast Updated:March 6, 2024Recruiting
Condition(s):Natural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeLast Updated:January 28, 2021Unknown status
Condition(s):Natural Killer T-cell LymphomaLast Updated:May 9, 2022Recruiting
Condition(s):Refractory and Relapsed T Cell LymphomaLast Updated:September 28, 2021Recruiting
Condition(s):T Cell LymphomaLast Updated:March 18, 2024Completed
Condition(s):NK/T Cell Lymphoma NosLast Updated:April 7, 2022Not yet recruiting
Condition(s):NK/T Cell LymphomaLast Updated:February 13, 2013Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.